Department of Anesthesia and Intensive Care, Cattinara University Hospital, Trieste, Italy.
J Crit Care. 2012 Apr;27(2):167-71. doi: 10.1016/j.jcrc.2011.05.012. Epub 2011 Jul 6.
Because the use of IgM and IgA enriched polyclonal intravenous immunoglobulins (eIg) is a standard of care in critically ill patients admitted to our intensive care unit (ICU) with the diagnosis of severe sepsis or septic shock, we investigated if the delay from the onset of severe sepsis and septic shock and their administration could influence the outcome.
The medical records of all patients with severe sepsis or septic shock admitted to our ICU from July 2004 through October 2009 and treated with eIg (Pentaglobin®; Biotest, Dreieich, Germany) were retrospectively examined.
A total of 129 adult patients with severe sepsis or septic shock were considered eligible. Thirty-two percent of patients died during the ICU stay. Survivors were given eIg significantly earlier than nonsurvivors (23 vs 63 hours, P < .05). The delay in the administration of eIg and the Simplified Acute Physiology Score II were the only variables that entered stepwise a propensity score-adjusted logistic model. The delay in the administration of eIg was a significant predictor of the odds of dying during the ICU stay (odds ratio for 1 hour of delay, 1.007; P < .01; 99% confidence interval from 1.001 to 1.010) and proved to be independent from the Simplified Acute Physiology Score II and other variables.
The efficacy of eIg, being maximal in early phases of severe sepsis and/or septic shock, is probably time dependent.
由于 IgM 和 IgA 浓缩型静脉用丙种球蛋白(eIg)的使用是入住我们重症监护病房(ICU)的严重脓毒症或脓毒性休克患者的标准治疗方法,因此我们研究了从严重脓毒症和脓毒性休克发作到开始使用 eIg 的时间延迟及其使用是否会影响结局。
回顾性检查了 2004 年 7 月至 2009 年 10 月入住我们 ICU 的所有严重脓毒症或脓毒性休克患者的病历,并对这些患者使用了 eIg(Pentaglobin®;Biotest,Dreieich,德国)进行治疗。
共纳入 129 例患有严重脓毒症或脓毒性休克的成年患者。32%的患者在 ICU 期间死亡。存活者接受 eIg 的时间明显早于非存活者(23 小时与 63 小时,P <.05)。eIg 给药时间延迟和简化急性生理学评分 II 是唯一进入倾向评分调整的逻辑回归模型的变量。eIg 给药时间延迟是 ICU 期间死亡的几率的显著预测因素(每延迟 1 小时的比值比为 1.007;P <.01;99%置信区间为 1.001 至 1.010),并且独立于简化急性生理学评分 II 和其他变量。
eIg 的疗效在严重脓毒症和/或脓毒性休克的早期阶段最大,可能与时间有关。